Search Results

You are looking at 71 - 80 of 1,490 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging?

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

backward selection of variables at a significance level of P <.10. An alpha threshold of 0.05 was chosen for statistical significance. Statistical analyses were performed using SPSS Statistics, version 24.0 (IBM Corp). Results Patient Characteristics A

Full access

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer

Vinayak Muralidhar, Paul J. Catalano, Gally Reznor, Brandon A. Mahal, Toni K. Choueiri, Christopher J. Sweeney, Neil E. Martin, Clair J. Beard, Yu-Wei Chen, Michelle D. Nezolosky, Karen E. Hoffman, Felix Y. Feng, Quoc-Dien Trinh, and Paul L. Nguyen

, treatment, and survival data in addition to patient-specific demographic characteristics, covering 28% of the US population and 97% of incident cancers. 12 SEER was linked to Medicare administrative data, which contains insurance claims data for patients

Full access

Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States

Iman K. Berrahou, Ava Snow, Megan Swanson, and Juno Obedin-Maliver

selected because of their particular relevance to the SGM population with regard to enumeration of protections in nondiscrimination policies across federal and state laws. Analyses were performed to determine whether cancer center characteristics impacted

Full access

Telemedicine Adoption in an NCI-Designated Cancer Center During the COVID-19 Pandemic: A Report on Patient Experience of Care

Krupal B. Patel, Amir Alishahi Tabriz, Kea Turner, Brian D. Gonzalez, Laura B. Oswald, Heather S.L. Jim, Oliver T. Nguyen, Young-Rock Hong, Nasrin Aldawoodi, Biwei Cao, Xuefeng Wang, Dana E. Rollison, Edmondo J. Robinson, Cristina Naso, and Philippe E. Spiess

the study period into the same 4 time intervals. Statistical Analyses Patient characteristics were summarized using descriptive statistics, including median and range for continuous measures and proportions and frequencies for categorical

Full access

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial

Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, Benoist Chibaudel, Lucile Bauguion, Leïla Bengrine-Lefevre, Daniel Lopez-Trabada Ataz, May Mabro, Jean-Philippe Metges, Denis Péré-Vergé, Thierry Conroy, Astrid Lièvre, Morgan Andre, Françoise Desseigne, François Goldwasser, Julie Henriques, Amélie Anota, and Pascal Hammel

study ( supplemental eAppendix 1 ), leading to the current version of the document. Clinical and biologic characteristics as well as baseline HRQoL scores were described in the overall, modified intention-to-treat [mITT] populations (mITT1: patients with

Full access

Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco

between 2006 and 2012 in the National Cancer Database (NCDB). The NCDB collects information from >1,500 Commission on Cancer centers and captures >70% of incident cancer cases in the United States. 11 We abstracted patient characteristics, including age

Full access

Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer

Boshen Jiao, Yaw A. Nyame, Josh J. Carlson, Louis P. Garrison Jr, and Anirban Basu

heterogeneity, it is appealing for clinicians to individualize treatment decisions according to relevant patient characteristics. 6 Our study focused on the case of abiraterone acetate + prednisone (AAP) as a treatment for metastatic hormone-sensitive prostate

Full access

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

representation of the progression-free survival. Data on TTF were only available for patients with complete follow-up (diagnosis in 2015–2016). Statistical Analysis Data in this study were analyzed using SAS 9.4 (SAS Institute Inc). Baseline characteristics

Full access

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer

Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le

, tumor site, and baseline ESAS-r Distress score. The target sample size was 100, based on our feasibility criteria for this 1-year study. We compared patient characteristics and PROs at baseline for screen-positive versus screen-negative patients, and for

Full access

Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer

Emily J. Martin, Andrew R. Bruggeman, Vinit V. Nalawade, Reith R. Sarkar, Edmund M. Qiao, Brent S. Rose, and James D. Murphy

(18.6%) underwent esophageal stent placement. Table 1 contains baseline patient characteristics stratified by intervention. The 2 groups differed in terms of race, tumor histology, tumor location in the esophagus, age, and Charlson comorbidity index